<i>ESR1</i> PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies

Liu, Xiaoqi; Huang, Jiawen; Lin, Huiran; Xiong, Lingjuan; Ma, Yunzi; Lao, Haiyan

doi:10.7150/jca.25638



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(16):2963-2972. doi:10.7150/jca.25638 This issue Cite

Review

ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies

Xiaoqi Liu^1,*, Jiawen Huang^2,*, Huiran Lin³, Lingjuan Xiong¹, Yunzi Ma¹, Haiyan Lao^1,✉

1. Department of Pharmacy, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China
2. Department of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong, China
3. Laboratory Animal Management Office, Public Service Platform for Science and Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China
*These authors contributed equally to this work.

Citation:

Liu X, Huang J, Lin H, Xiong L, Ma Y, Lao H. ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies. J Cancer 2018; 9(16):2963-2972. doi:10.7150/jca.25638. https://www.jcancer.org/v09p2963.htm

Other styles

Abstract

Emerging epidemiological researches have been performed to assess the association of ESR1 PvuII (rs2234693 T>C) polymorphism with the risk of cancer, yet with conflicting conclusions. Therefore, this updated meta-analysis was performed to make a more accurate evaluation of such relationship. We adopted EMBASE, PubMed, CNKI, and WANFANG database to search relevant literature before January 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were employed to estimate the relationship strengths. In final, 80 studies (69 publications) involving 26428 cases and 43381 controls were enrolled. Our results failed to provide significant association between overall cancer risk and PvuII polymorphism under homozygous (TT vs. CC) and heterozygous (TT vs. CT) models. Statistically significant relationship was only observed for PvuII polymorphism in allele model T vs. C (OR=0.95, 95% CI=0.91-0.99). Stratification analysis by cancer type suggested that T genotype significantly decreased prostate cancer risk (TT vs. CC: OR=0.79, 95% CI=0.66-0.94; T vs. C: OR=0.89, 95% CI=0.82-0.98), Leiomyoma risk (T vs. C: OR=0.82, 95% CI=0.68-0.98), and HCC risk (TT vs. CC: OR=0.45, 95% CI=0.28-0.71; T vs. C: OR=0.67, 95% CI=0.47-0.95). Furthermore, significantly decreased risk was also found for Africans, population-based and hospital-based studies in the stratified analyses. These results suggest that ESR1 PvuII (rs2234693 T>C) polymorphism may only have little impact on cancer susceptibility. In the future, large-scale epidemical studies are warranted to verify these results.

Keywords: meta-analysis, ESR1, PvuII, polymorphism, cancer risk

Citation styles

APA

Liu, X., Huang, J., Lin, H., Xiong, L., Ma, Y., Lao, H. (2018). ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies. Journal of Cancer, 9(16), 2963-2972. https://doi.org/10.7150/jca.25638.

ACS

Liu, X.; Huang, J.; Lin, H.; Xiong, L.; Ma, Y.; Lao, H. ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies. J. Cancer 2018, 9 (16), 2963-2972. DOI: 10.7150/jca.25638.

NLM

CSE

Liu X, Huang J, Lin H, Xiong L, Ma Y, Lao H. 2018. ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies. J Cancer. 9(16):2963-2972.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.